Found: 5
Select item for more details and to access through your institution.
Impact of body mass index on the prognosis of unresectable HCC patients receiving first‐line Lenvatinib or atezolizumab plus bevacizumab.
- Published in:
- Liver International, 2024, v. 44, n. 5, p. 1108, doi. 10.1111/liv.15885
- By:
- Publication type:
- Article
α‐FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma.
- Published in:
- International Journal of Cancer, 2024, v. 154, n. 6, p. 1043, doi. 10.1002/ijc.34799
- By:
- Publication type:
- Article
Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab.
- Published in:
- Targeted Oncology, 2024, v. 19, n. 4, p. 645, doi. 10.1007/s11523-024-01061-0
- By:
- Publication type:
- Article
Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab.
- Published in:
- Targeted Oncology, 2024, v. 19, n. 2, p. 223, doi. 10.1007/s11523-024-01032-5
- By:
- Publication type:
- Article
Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma.
- Published in:
- Targeted Oncology, 2024, v. 19, n. 1, p. 29, doi. 10.1007/s11523-023-01029-6
- By:
- Publication type:
- Article